Curcumin compound reactivates Epstein–Barr virus, offering safer cancer therapy

A novel curcumin derivative, C210, activates the Epstein–Barr virus (EBV) lytic cycle without producing infectious virions by disrupting HSP90. This discovery opens avenues for safer EBV-positive cancer therapies.

Presidential debate moderators should ask about mental health policy

As the mom of three young adults, I am worried about their economic future — their ability to get jobs and afford homes. But I

September 6, 2024

Novel combination therapy shows promise in difficult-to-treat endometrial cancer, study finds

In a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed

April 5, 2024

Tomivosertib hydrochloride by EFFECTOR Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

October 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.